Filtered By:
Drug: Prednisolone
This page shows you your search results in order of date. This is page number 9.
Order by Relevance | Date
Total 367 results found since Jan 2013.
Itraconazole Improved Bronchial Wall Thickness in Severe Persistent Asthma: A Double-blind Placebo-controlled Randomized Clinical Trial
Iran J Allergy Asthma Immunol. 2023 Feb 20;22(1):1-11. doi: 10.18502/ijaai.v22i1.12000.ABSTRACTThe purpose of this study was to evaluate the effect of 8 months of treatment with itraconazole on airway wall thickness in patients with severe persistent asthma. It was a double-blind, randomized, placebo-controlled clinical trial (IRCT20091111002695N9). Seventy-five subjects with severe persistent asthma received itraconazole (100 mg), prednisolone (5 mg), or placebo twice a day for eight months in three treatment groups (n=25 in each group). The primary objective was to improve the right upper lobe apical segmental bronchus (...
Source: Iranian Journal of Allergy, Asthma and Immunology - April 1, 2023 Category: Allergy & Immunology Authors: Farnaz Aligolighasemabadi Majid Mirsadraee Mohammadamin Sadeghdoust Shadi Ghaffari Mohammad Sarafraz Yazdi Saeed Naghibi Amirhossein Hashemi Attar Source Type: research
Analysis of lung lavage granulocyte constituents and blood type 2 biomarkers does not support routine use of corticosteroids in children with problematic wheeze
The author appreciates Dr Weinberger's letter of response to the Perspective published in the Annals of Asthma Allergy& Immunology in December 2022.1,2 The author advocates, based on supporting data, consideration of diagnostic bronchoscopy and lung lavage granulocyte profiles as a foundation for treatment of preschool children with therapy-resistant problematic wheeze. Dr Weinberger correctly points out that the summary of the study of Wallace et al,3 a placebo-controlled trial wherein prednisolone treatment of preschool children with acute wheeze failed to improve 24-hour respiratory assessment scores compared with placebo, was incomplete.
Source: Annals of Allergy, Asthma and Immunology - March 31, 2023 Category: Allergy & Immunology Authors: W. Gerald Teague Tags: Correspondence Source Type: research
Short courses of oral corticosteroids are effective, important, and safe for virus-triggered wheeze
Dr Teague1 begins his interesting Perspective with the statement that prednisolone for acute episode of virus-triggered wheeze is not supported by convincing evidence for efficacy, referencing a study by Wallace et al.2 However, although Wallace et al2 state a conclusion that oral prednisolone did not alter respiratory outcomes in preschool children with acute wheeze, the data from that study do not support that conclusion. Hospital admissions and use of open-label prednisolone were statistically significantly and substantially less in the prednisolone-treated patients.
Source: Annals of Allergy, Asthma and Immunology - March 31, 2023 Category: Allergy & Immunology Authors: Miles Weinberger Tags: Correspondence Source Type: research
Effect of Baseline Blood Eosinophil Level on Asthma Exacerbations Among Patients Treated with Benralizumab During the Oral Corticosteroid Reduction Phase of the PONENTE Trial
The PONENTE trial evaluated the effectiveness and safety of a rapid, individualized algorithm for reducing oral corticosteroid (OCS) use after initiation of benralizumab in patients with uncontrolled severe eosinophilic asthma (SEA). Overall, 81.9% of patients eliminated OCS or reduced their daily dose to ≤5 mg prednisone/prednisolone. For this analysis, we examined the effect of baseline blood eosinophil (bEOS) level on asthma exacerbations during the OCS reduction phase of PONENTE.
Source: Journal of Allergy and Clinical Immunology - February 1, 2023 Category: Allergy & Immunology Authors: Justin Kwiatek, Ryan Finch, Lynda Olinger, Rohit Katial, Liam Heaney Source Type: research
